Tumor drug-response & genomic biomarker testing
Identify effective treatments for cancer patients.
Cancer is personal. For many years, our clinically validated tumor drug-response testing (ChemoFx® from Helomics) and genomic biomarker testing have used live patient tumor cells to help physicians identify effective treatment options for that specific patient. This technology helps clinicians rule out chemotherapies that won’t work—and focus on those that are more likely to deliver better outcomes.
Helomics is now part of Predictive Oncology.
Our tumor drug-response testing is associated with a 50% improvement in progression-free survival and a 14-month improvement in overall survival when patients receive a sensitive therapy. In fact, patients treated with a sensitive agent identified by our testing lived 2.5 times longer than patients treated with a resistant agent. Source
What can testing do for your patients?
Our testing can help identify treatments that are more likely to work to treat specific patients—quickly and cost-efficiently. In fact, full reports are usually delivered within just a few weeks of tissue receipt and insurance may cover the cost of testing.
Our reports show the full spectrum of potential treatment efficacy—categorizing multiple treatments to show which will likely be the most effective, least effective and possibly effective.
Our genomic biomarker testing can help identify platinum sensitivity and resistance up front—before finding out the hard way when a patient’s cancer comes back post-treatment. What’s more, our testing demonstrated the ability to identify potentially effective treatments for the majority (59%) of platinum-resistant patients.
Get in touch to order tests.
Complete the form with questions about future or previous tests.